Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting (pages 200–207)Anne L. Abbott, Mark A. A. Adelman, Andrei V. Alexandrov, Henry J. M. Barnett, Jonathan Beard, Peter Bell, Martin Björck, David Blacker, Clifford J. Buckley, Richard P. Cambria, Anthony J. Comerota, E. Sander Connolly, Alun H. Davies, Hans-Henning Eckstein, R. Faruqi, Gustav Fraedrich, Peter Gloviczki, Graeme J. Hankey, Robert E. Harbaugh, E. Heldenberg, Steven J. Kittner, Timothy J. Kleinig, Dimitri P. Mikhailidis, Wesley S. Moore, R. Naylor, Andrew Nicolaides, Kosmas I. Paraskevas, David M. Pelz, James W. Prichard, Grant Purdie, Jean-Baptiste Ricco, Thomas Riles, Peter Rothwell, Peter Sandercock, Henrik Sillesen, J. David Spence, Francesco Spinelli, Aron Tan, Ankur Thapar, Frank J. Veith and Wei Zhou
Article first published online: 19 MAR 2012 | DOI: 10.1002/brb3.32

Why carotid angioplasty/stenting is not indicated for asymptomatic carotid stenosis or ‘low/standard CEA risk’ symptomatic carotid stenosis.